Definition of ‘Medical Devices’ Amended in the FDI Policy

admin
admin
· 2 min read
Medical Devices

The Union Cabinet chaired by the Prime Minister Shri Narendra Modi, has given its approval to a number of amendments in the FDI Policy. These are intended to liberalise and simplify the FDI policy so as to provide ease of doing business in the country. In turn, it will lead to larger FDI inflows contributing to growth of investment, income and employment.

Foreign Direct Investment (FDI) is a major driver of economic growth and a source of non-debt finance for the economic development of the country. Government has put in place an investor friendly policy on FDI, under which FDI up to 100%, is permitted on the automatic route in most sectors/ activities. In the recent past, the Government has brought FDI policy reforms in a number of sectors viz. Defence, Construction Development, Insurance, Pension, Other Financial Services, Asset reconstruction Companies, Broadcasting, Civil Aviation, Pharmaceuticals, Trading etc.

FDI policy on Pharmaceuticals sector inter-alia provides that definition of medical device as contained in the FDI Policy would be subject to amendment in the Drugs and Cosmetics Act. As the definition as contained in the policy is complete in itself, it has been decided to drop the reference to Drugs and Cosmetics Act from FDI policy. Further, it has also been decided to amend the definition of ‘medical devices’ as contained in the FDI Policy.

“This is just housekeeping and tidying up”, said Rajiv Nath, Forum Coordinator, (AiMeD) Association of Indian Medical Device Industry.

“DoP should learn from DiPP and MoH&FW and delink Devices from Pharmaceutical after treating Devices as sub sector of Pharmaceutical (Drugs ). Both are medical healthcare products but different and need different policies to boost investment in this sector. We have always welcomed 100% Greenfield investment in India for Medical Devices but are opposed to 100% Auto route without oversight of DoP for brownfield takeover of the few indigenous medical device manufacturers who have been providing an alternate affordable access to Cost effective Desi Brands ” said Nath.

Read Next

Annora Pharma Expands Collaboration with AI-Native Traceability Platform AltiusHub to Strengthen Global Drug Traceability
News
May 18, 2026

Annora Pharma Expands Collaboration with AI-Native Traceability Platform AltiusHub to Strengthen Global Drug Traceability

Annora Pharma, the formulations subsidiary of Hetero Group, has expanded its collaboration with AltiusHub. The company is deploying AltiusHub’s AI-native serialization, track & trace and regulatory compliance platform across its export operations. The deployment is designed to improve serialization efficiency by up to 45%. It will also strengthen operational visibility across Annora Pharma’s global supply […]
Article by: IMT News Desk
WFNS Innovation & Technology Committee Announces Partnership with Time Medical International Ventures (India) Pvt Ltd for First-in-Class Medical Technology Innovation
News
May 18, 2026

WFNS Innovation & Technology Committee Announces Partnership with Time Medical International Ventures (India) Pvt Ltd for First-in-Class Medical Technology Innovation

The World Federation of Neurosurgical Societies (WFNS) Innovation & Technology Committee has announced collaboration with Time Medical International Ventures (India) Pvt. Ltd (Time Medical India)., a wholly owned subsidiary of Fischer Medical Ventures Limited, marking a significant milestone in advancing innovation in global neurosurgical care. This marks the first time the Committee has formally partnered […]
Article by: IMT News Desk
National AI Doctors Mission launches in New Delhi: How AI will change Indian healthcare
News
May 18, 2026

National AI Doctors Mission launches in New Delhi: How AI will change Indian healthcare

The National AI Doctors Mission (NAIDM) has been formally launched in New Delhi, marking a major step toward integrating artificial intelligence into everyday clinical practice across India’s public and private healthcare system. The initiative, led by Medical Dialogues in collaboration with the National Medical Forum, aims to make AI “useful and usable” for frontline doctors rather than […]
Article by: IMT News Desk
Gland Pharma rallies on upbeat Q4; profit soars 97% YoY to ₹367 crore
News
May 18, 2026

Gland Pharma rallies on upbeat Q4; profit soars 97% YoY to ₹367 crore

Gland Pharma shares extended gains in the capital markets after the company posted a standout Q4 performance, with consolidated net profit jumping 97% year‑on‑year to ₹367 crore, riding on a sharp improvement in operating leverage and a strong base‑business showing in the US. Revenue for the quarter rose 22% YoY to ₹1,743 crore, while EBITDA surged 48% YoY […]
Article by: IMT News Desk